Warren Huff | Chairman and Chief Executive Officer |
Dawn Bir | Executive Vice President and Chief Commercial Officer |
Andrea Loewen | Senior Vice President of Global Regulatory Affairs |
Seemi Khan | Senior Vice President and Chief Medical Officer |
Colin Meyer | Executive Vice President and Chief Innovation Officer |
Manmeet Soni | President, Chief Operating Officer and Chief Financial Officer |
Yigal Nochomovitz | Citigroup |
Madhu Kumar | Goldman Sachs |
Yatin Suneja | Guggenheim Securities |
Charles Duncan | Cantor Fitzgerald |
Carter Gould | Barclays |
Annabel Samimy | Stifel |
Maury Raycroft | Jefferies |
Matthew Kaplan | Ladenburg Thalmann |
Thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter Financial Results Update on Operational Progress and Development Programs Conference Call. An audio recording of today’s webcast will be available shortly after the call in the Investor section of Reata’s website at reatapharma.com.
Before the Company proceeds with its remarks, please note the forward-looking statements disclosure in the Company’s press release. There are many factors that could cause results to differ from expectations, including those noted in the Company’s SEC filings. Today’s statements are not guarantees of future outcomes.